E3E4E7DA-AD14-44BA-B3BE-02652B3CEE18
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.19710906701708278
- age_years
- 44
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.521
- OXIDATIVE_PHOSPHORYLATION+0.518
- MYC_TARGETS_V1+0.456
- DNA_REPAIR+0.426
- PROTEIN_SECRETION+0.363
- E2F_TARGETS+0.338
- MYC_TARGETS_V2+0.335
- G2M_CHECKPOINT+0.308
- ADIPOGENESIS+0.297
- MITOTIC_SPINDLE+0.277
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.395
- IL6_JAK_STAT3_SIGNALING-0.384
- ANGIOGENESIS-0.357
- TNFA_SIGNALING_VIA_NFKB-0.357
- ALLOGRAFT_REJECTION-0.349
- KRAS_SIGNALING_DN-0.340
- INTERFERON_GAMMA_RESPONSE-0.338
- COAGULATION-0.333
- APICAL_SURFACE-0.325
- COMPLEMENT-0.312
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030833_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.899 |
| 2 | SJEPD030743_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.895 |
| 3 | 2C70D7BF-85C4-447B-B0F9-A129D6B49E77 | — | — | 0.890 |
| 4 | 713B4DA5-FA8A-4E52-BACF-19B912467FBB | — | — | 0.884 |
| 5 | 2CF24C43-7C9D-4395-8C82-5A80361F9980 | — | — | 0.881 |
| 6 | 1C94EA93-563D-4F65-B857-85EF91127874 | — | — | 0.879 |
| 7 | A85A0E3A-2CB9-40EB-80E9-125EC137151B | — | — | 0.873 |
| 8 | E528D9EE-41C3-4D4C-B16F-ABBDD6E31B84 | — | — | 0.869 |
| 9 | E3A67B7B-7427-4C11-912B-166451072767 | — | — | 0.867 |
| 10 | MNG1053 | — | — | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.521 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.518 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.456 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.426 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.363 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.338 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.335 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.308 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.297 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.277 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.232 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.208 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.207 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.191 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.186 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.171 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.165 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.133 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.103 | Inavolisib | — uncovered |